title: Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: Fertility risk of Food and Drug Administration-approved systemic therapies.
abstract: BACKGROUND
  Melanoma is the most common cancer diagnosed for patients ages 25 to 29 years, the group with the highest birth rates in the United States. Oncofertility is a new field addressing the reproductive needs of patients with cancer facing fertility-threatening treatments.
  
  
  OBJECTIVE
  We sought to assess gender-specific fertility risk for Food and Drug Administration (FDA)-approved melanoma therapies with a new risk category system.
  
  
  METHODS
  We conducted a retrospective review of FDA, European Union, and Health Canada regulatory filings, along with previously published reports to grade fertility risk of systemic melanoma therapies. The proposed fertility risk category system is analogous to the FDA's A/B/C/D/X/N pregnancy-risk categories.
  
  
  RESULTS
  For female patients, 58% of treatments represent a fertility risk (Category C and D), 33% have unknown risk (Category N), and 1 therapy (vemurafenib) did not show animal ovarian toxicity (Category B). For male patients, 33% represented a fertility risk (Category C and D), 50% of treatments had unknown risk (Category N), and 17% did not show animal testicular toxicity (Category B).
  
  
  CONCLUSIONS
  Data on fertility risk for melanoma therapies approved after 2009 are limited to preclinical animal studies.
  
  
  CONCLUSIONS
  Dermatologists have an opportunity to discuss fertility preservation, make appropriate referrals, and steward registries on reproductive outcomes for patients with melanoma.
authors.affiliation: Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: Walter
authors.affiliation: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Shuai
authors.initials: S
authors.lastname: Xu
authors.affiliation: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Amy S
authors.initials: AS
authors.lastname: Paller
authors.affiliation: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors.forename: Jennifer N
authors.initials: JN
authors.lastname: Choi
authors.affiliation: Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.|Women's Health Research Institute, Northwestern University, Chicago, Illinois.
authors.forename: Teresa K
authors.initials: TK
authors.lastname: Woodruff
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002170:Canada; D015331:Cohort Studies; D003376:Counseling / Q000458:organization & administration; D005062:European Union; D005260:Female; D059247:Fertility Preservation / Q000379:methods*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000517:prevention & control; D007248:Infertility, Male / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008545:Melanoma / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D011247:Pregnancy; D012189:Retrospective Studies; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents
keywords: cancer survivorship; melanoma; oncofertility